GlassScriptPhysician profile
Randi D True
NPI 1326363128
$3,335.20
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,586 · 2022: $1,705 · 2023: $44.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.70 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $340.45 | 2021-2022 | |
| Novo Nordisk INC | $312.63 | 2021-2023 | Wegovy |
| Glaxosmithkline, LLC. | $205.20 | 2021-2022 | |
| Amgen INC. | $157.85 | 2021-2022 | |
| Amarin Pharma, INC. | $155.62 | 2021-2022 | |
| Lilly USA, LLC | $134.00 | 2021-2023 | Mounjaro |
| Abbott Laboratories | $126.30 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $119.06 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $109.10 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $101.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.50 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $93.17 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.16 | 2021-2022 | |
| Astellas Pharma US INC | $76.87 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.34 | 2021-2022 | |
| Scynexis, INC. | $42.16 | 2022 | |
| Lundbeck LLC | $40.46 | 2022 | |
| Viiv Healthcare Company | $40.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.76 | 2021 | |
| Antares Pharma, INC. | $33.41 | 2021 | |
| Supernus Pharmaceuticals, INC. | $31.04 | 2021 | |
| Jazz Pharmaceuticals INC. | $30.97 | 2021 | |
| Si-Bone, INC. | $30.79 | 2021 | |
| Genentech USA, INC. | $23.72 | 2021 | |
| Gilead Sciences, INC. | $22.88 | 2022 | |
| Tris Pharma INC | $22.54 | 2022 | |
| Dexcom, INC. | $19.06 | 2022 | |
| Althera Pharmaceuticals LLC | $17.05 | 2022 | |
| Becton, Dickinson and Company | $15.20 | 2021 | |
| Cranial Technologies, INC | $14.99 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.68 | 2022 | |
| Kaleo, INC. | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi True listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.